Evidence map›Paper›PMID 37782053›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2023

Myeloid Heterogeneity Mediates Acute Exacerbations of Pulmonary Fibrosis.

Jennifer L Larson-Casey, Komal Saleem, Ranu Surolia, Jyotsana Pandey, Matthias Mack, Veena B Antony, Sandeep Bodduluri, Surya P Bhatt, Steven R Duncan, A Brent Carter

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Jennifer L Larson-CaseyDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-7238-7986
Komal SaleemDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0009-0008-5273-1960
Ranu SuroliaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Jyotsana PandeyDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Matthias MackDepartment of Nephrology, University of Regensburg, Regensburg, Germany.
Veena B AntonyDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Sandeep BodduluriDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Surya P BhattDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-8418-4497
Steven R DuncanDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
A Brent CarterDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-6002-4715
University of Alabama at Birmingham · USUniversity of Regensburg · DE

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
Project 5 Nano-micro Hybrid Fibrous Materials for Containment Removal and Site RemediationP42ES027723 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LUNGU, CLAUDIU T · 2020 to 2024
$6.7M
Lung Macrophage Metabolic Reprogramming in Asbestos-Induced ToxicityR01ES015981 · NIEHS · UNIVERSITY OF IOWA · PI CARTER, A BRENT · 2007 to 2022
$5.5M
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary FibrosisU01HL133232 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CRINER, GERARD J, DUNCAN, STEVEN R · 2017 to 2021
$3.8M
Structural Determinants of Disease Progression in COPDR01HL151421 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATT, SURYA P., NAKHMANI, ARIE · 2020 to 2024
$2.6M
Environmental Cadmium and COPDR01ES029981 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANTONY, VEENA B. · 2018 to 2022
$2.5M
Pulmonary fibrosis is modulated by MCU-mediated macrophage apoptosis resistanceI01CX001715 · VA · BIRMINGHAM VA MEDICAL CENTER · PI CARTER, A BRENT · 2019 to 2023
–
CSRD VA I01 CX001715NCI NIH HHS P30 CA013148NHLBI NIH HHS R01 HL151421NHLBI NIH HHS U01 HL133232NIAID NIH HHS P30 AI027767NIEHS NIH HHS P42 ES027723NIEHS NIH HHS R01 ES015981NIEHS NIH HHS R01 ES029981
6 · The paper itself

Abstract

Epidemiological evidence indicates that exposure to particulate matter is linked to the development of idiopathic pulmonary fibrosis (IPF) and increases the incidence of acute exacerbations of IPF. In addition to accelerating the rate of lung function decline, exposure to fine particulate matter (particulate matter smaller than 2.5 μm [PM2.5]) is a risk factor for increased mortality in subjects with IPF. In this article, we show that exposure to PM2.5 mediates monocyte recruitment and fibrotic progression in mice with established fibrosis. In mice with established fibrosis, bronchoalveolar lavage cells showed monocyte/macrophage heterogeneity after exposure to PM2.5. These cells had a significant inflammatory and anti-inflammatory signature. The mixed heterogeneity of cells contributed to the proinflammatory and anti-inflammatory response. Although monocyte-derived macrophages were recruited to the lung in bleomycin-injured mice treated with PM2.5, recruitment of monocytes expressing Ly6Chi to the lung promoted progression of fibrosis, reduced lung aeration on computed tomography, and impacted lung compliance. Ly6Chi monocytes isolated from PM2.5-exposed fibrotic mice showed enhanced expression of proinflammatory markers compared with fibrotic mice exposed to vehicle. Moreover, IPF bronchoalveolar lavage cells treated ex vivo with PM2.5 showed an exaggerated inflammatory response. Targeting Ly6Chi monocyte recruitment inhibited fibrotic progression in mice. Moreover, the adoptive transfer of Ly6Chi monocytes exacerbated established fibrosis. These observations suggest that enhanced recruitment of Ly6Chi monocytes with a proinflammatory phenotype mediates acute exacerbations of pulmonary fibrosis, and targeting these cells may provide a potential novel therapeutic target to protect against acute exacerbations of IPF.

Indexed as

Idiopathic Pulmonary FibrosisLungAnimalsAnti-Inflammatory AgentsBleomycinFibrosisHumansMiceParticulate MatterAnti-Inflammatory AgentsBleomycinParticulate Matter

Identifiers

PMID37782053
PMCPMC10843506
OpenAlexW4387241862

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.